Vicky Cory (@VCory) header
Vicky Cory (@VCory) profile picture

Vicky Cory

@VCory

Just Keep Smiling.

 Overland Park, KS
Joined July 2009
  • Tweets192
  • Following111
  • Followers64
48Media
Photo by Vicky Cory (@VCory)Photo by Vicky Cory (@VCory)Photo by Vicky Cory (@VCory)Photo by Vicky Cory (@VCory)Photo by Vicky Cory (@VCory)Photo by Vicky Cory (@VCory)Photo by Vicky Cory (@VCory)Photo by Vicky Cory (@VCory)Photo by Vicky Cory (@VCory)
Vicky Cory retweeted
KCTV5 News (@KCTV5) profile picture
KCTV5 News@KCTV515 Mar 2025
The Kansas Department of Health and Environment issued an Air Quality Health Advisory on March 14 due to extreme winds pushing dust and smoke throughout the state. kctv5.com/2025/03/14/air-qua…
Air Quality Health Advisory issued by KDHE due to dust, smoke after strong winds

Air Quality Health Advisory issued by KDHE due to dust, smoke after strong winds

Smoke and dust are blowing around due to strong winds, which caused KDHE to issue an Air Quality Health Advisory.

kctv5.com
1
5
5
3,489
(1) New Messages! eversana.com/2023/07/24/ever…

EVERSANA & Amazon Web Services to “Pharmatize” Artificial Intelligence across the Life Sciences...

eversana.com
19
Exceeding Budgets & Falling Short: EVERSANA Leaders Tell Hard Truths About Omnichannel - eepurl.com/ikcwy1

Exceeding Budgets & Falling Short: EVERSANA Leaders Tell Hard Truths About Omnichannel

EVERSANA leaders are raising the question the industry has been too afraid to ask aloud: Has omnichannel lived up to its promise?

eversanaintouch.com
22
Onwards & Upwards - The Conundrums Live Performance youtu.be/GpQliDP4Ric via @YouTube
Onwards & Upwards - Live Performance

Onwards & Upwards - Live Performance

Performance of The Conundrums original song (and Grayson's favorite...

youtube.com
Being named a 2022 PM360 Trailblazer Advertising Agency CEO of the Year is just one of many reasons we’re proud to have @farukcapan as our fearless leader. Congrats on the well-deserved recognition! bit.ly/3SqPBfw #PM360Trailblazers
Image from EVERSANA INTOUCH (@EVERSANAINTOUCH)
1
1
3
Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual Meeting globenewswire.com/news-relea…
Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the...

Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the...

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical...

globenewswire.com
Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate) globenewswire.com/news-relea…
Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)

Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical...

globenewswire.com
Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results globenewswire.com/news-relea…

Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results

NORTHBROOK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to...

globenewswire.com
Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis globenewswire.com/news-relea…
Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone...

Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone...

Initial focus for CLAR-121 is the treatment of periductal mastitis (PDM) in women Clarus is seeking Orphan Drug Designation from the U.S. Food and Drug...

globenewswire.com
Exciting pipeline news for team Clarus!
Clarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public Offering globenewswire.com/news-relea…

Clarus Therapeutics Announces Pricing of Upsized $30.0 Million Underwritten Public Offering

NORTHBROOK, Ill., April 25, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to...

globenewswire.com
Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the Androgen Society 4th Annual Meeting globenewswire.com/news-relea…
Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the Androgen...

Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at the Androgen...

JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical...

globenewswire.com
Clarus Announces Initiation of Phase 4 Clinical Trial of JATENZO® (testosterone undecanoate) for the Treatment of Hypogonadal Men with Chronic Kidney Disease globenewswire.com/news-relea…
Clarus Announces Initiation of Phase 4 Clinical Trial of JATENZO® (testosterone undecanoate) for...

Clarus Announces Initiation of Phase 4 Clinical Trial of JATENZO® (testosterone undecanoate) for...

JATENZO is the first and only FDA-approved oral softgel for testosterone (T) replacement therapy in adult males who have deficient T due to certain medical...

globenewswire.com
Go Clarus! Clarus Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference globenewswire.com/news-relea…
Clarus Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference

Clarus Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference

NORTHBROOK, Ill., March 10, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to...

globenewswire.com
Clarus Announces Strategic Partnerships for JATENZO® (testosterone undecanoate) with Vault Health and AssistRx – Leaders in Providing Healthcare Services to Patients globenewswire.com/news-relea…
Clarus Announces Strategic Partnerships for JATENZO® (testosterone undecanoate) with Vault Health...

Clarus Announces Strategic Partnerships for JATENZO® (testosterone undecanoate) with Vault Health...

JATENZO is the first and only FDA-approved oral softgel capsule for testosterone replacement therapy in adult males who have deficient testosterone due to...

globenewswire.com
1
Clarus Announces Strategic Partnerships for JATENZO® (testosterone undecanoate) with Vault Health and AssistRx – Leaders in Providing Healthcare Services to Patients globenewswire.com/news-relea…
Clarus Announces Strategic Partnerships for JATENZO® (testosterone undecanoate) with Vault Health...

Clarus Announces Strategic Partnerships for JATENZO® (testosterone undecanoate) with Vault Health...

JATENZO is the first and only FDA-approved oral softgel capsule for testosterone replacement therapy in adult males who have deficient testosterone due to...

globenewswire.com
SCHOOLS CLOSED - Due to inclement weather all schools are closed Wednesday, February 21.
19
87
10
290
We are excited that Dr. Zhanna Jumadilova has joined Clarus as Chief Clinical Development Officer! Read more: bit.ly/3nABh77 #ClarusThera #CRXT #welcometotheteam
2
4
Clarus Therapeutics Announces $15 Million Private Placement globenewswire.com/news-relea…

Clarus Therapeutics Announces $15 Million Private Placement

Proceeds to support the ongoing commercialization of JATENZO® (testosterone undecanoate) NORTHBROOK, Ill., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Clarus...

globenewswire.com
Clarus Therapeutics to Report Third Quarter 2021 Financial and Operating Results globenewswire.com/news-relea…

Clarus Therapeutics to Report Third Quarter 2021 Financial and Operating Results

NORTHBROOK, Ill., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to...

globenewswire.com
Load more